The value of laboratory data in creating custom test panels

Paradigm uses its laboratory data to help its clients update custom test panels and documentation for medically necessary testing. This issue of the Paradigm Shift is dedicated to summarizing payor positions on blanket orders, standing orders, and medically necessary drug testing. We wish everyone a happy and healthy New Year and we look forward to [...]

By |2020-12-07T20:48:39+00:00December 7th, 2020|Laboratory Data, Newsletter|Comments Off on The value of laboratory data in creating custom test panels

Laboratory Data: Know Your Practice. Know Your Patients.

Message from Paradigm’s President, Catherine Veal What a whirlwind this Spring has been for us all! At Paradigm, we’ve stayed very busy throughout the COVID-19 public health emergency and we’re looking forward to helping our clients as they continue telemedicine visits and return to in-person encounters with their patients. Our Benchmark® Presumptive LC-MS/MS testing [...]

By |2020-06-09T14:30:46+00:00June 8th, 2020|Laboratory Data, Newsletter|1 Comment

COVID, Telemedicine and Drug Testing

We know many of you are finding your way through the COVID-19 Public Health Emergency (COVID-19 PHE) and shifting from traditional in-person healthcare practice settings to telemedicine encounters with your patients. We understand that telemedicine presents a significant challenge on many levels, especially when controlled medication is part of the treatment plan. For these [...]

By |2020-06-09T14:20:07+00:00April 5th, 2020|COVID-19 and DEA, Newsletter|0 Comments

DEA and State Positions – Controlled Drugs During the Era of the COVID-19 PHE

Understanding DEA and State Positions on Prescribing Controlled Medication During the COVID-19 Public Health Emergency Paradigm Labs is doing its part to support healthcare providers and their patients during the COVID-19 Public Health Emergency (COVID-19 PHE). To this end, Paradigm Labs has developed a drug testing platform that allows providers and patients to engage [...]

By |2020-06-09T14:50:26+00:00March 30th, 2020|COVID-19 and DEA, Newsletter, Regulatory|0 Comments